Erasca Exercises Option to Extend Cancer Drug Candidate License to Gain Global Rights

MT Newswires Live03-10

Erasca (ERAS) said Tuesday it has exercised an option under its licensing agreement with Joyo Pharmatech to include China, Hong Kong and Macau, giving the company worldwide rights to the cancer drug candidate ERAS-0015.

The company said the decision converts its existing territorial license into worldwide coverage and requires a one-time payment to Joyo tied to the stage of the partner's development program.

Erasca said the expanded rights allow it to pursue development and potential commercialization of ERAS-0015 under a single global strategy.

The drug candidate is being studied in a phase 1 dose escalation trial in patients with tumors driven by RAS mutations, Erasca said, adding that initial results are expected in H1.

Financial terms were not disclosed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618953846?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 20:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618953846","market":"nz","top_or_hot":-1,"title":"Erasca Exercises Option to Extend Cancer Drug Candidate License to Gain Global Rights","media":"MT Newswires Live","content":"<html><body><p> Erasca (ERAS) said Tuesday it has exercised an option under its licensing agreement with Joyo Pharmatech to include China, Hong Kong and Macau, giving the company worldwide rights to the cancer drug candidate ERAS-0015.</p><p>The company said the decision converts its existing territorial license into worldwide coverage and requires a one-time payment to Joyo tied to the stage of the partner's development program.</p><p>Erasca said the expanded rights allow it to pursue development and potential commercialization of ERAS-0015 under a single global strategy.</p><p>The drug candidate is being studied in a phase 1 dose escalation trial in patients with tumors driven by RAS mutations, Erasca said, adding that initial results are expected in H1.</p><p>Financial terms were not disclosed.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Erasca Exercises Option to Extend Cancer Drug Candidate License to Gain Global Rights</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErasca Exercises Option to Extend Cancer Drug Candidate License to Gain Global Rights\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-10 20:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Erasca (ERAS) said Tuesday it has exercised an option under its licensing agreement with Joyo Pharmatech to include China, Hong Kong and Macau, giving the company worldwide rights to the cancer drug candidate ERAS-0015.</p><p>The company said the decision converts its existing territorial license into worldwide coverage and requires a one-time payment to Joyo tied to the stage of the partner's development program.</p><p>Erasca said the expanded rights allow it to pursue development and potential commercialization of ERAS-0015 under a single global strategy.</p><p>The drug candidate is being studied in a phase 1 dose escalation trial in patients with tumors driven by RAS mutations, Erasca said, adding that initial results are expected in H1.</p><p>Financial terms were not disclosed.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618953846","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618953846","pubTimestamp":1773147492,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Erasca  said Tuesday it has exercised an option under its licensing agreement with Joyo Pharmatech to include China, Hong Kong and Macau, giving the company worldwide rights to the cancer drug candidate ERAS-0015.The company said the decision converts its existing territorial license into worldwide coverage and requires a one-time payment to Joyo tied to the stage of the partner's development program.Erasca said the expanded rights allow it to pursue development and potential commercialization of ERAS-0015 under a single global strategy.The drug candidate is being studied in a phase 1 dose escalation trial in patients with tumors driven by RAS mutations, Erasca said, adding that initial results are expected in H1.Financial terms were not disclosed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ERAS":"Erasca, INC.","BK4139":"生物科技"},"translate_title":"Erasca行使选择权延长癌症候选药物许可以获得全球权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1.5},"content_text":"Erasca (ERAS) said Tuesday it has exercised an option under its licensing agreement with Joyo Pharmatech to include China, Hong Kong and Macau, giving the company worldwide rights to the cancer drug candidate ERAS-0015.The company said the decision converts its existing territorial license into worldwide coverage and requires a one-time payment to Joyo tied to the stage of the partner's development program.Erasca said the expanded rights allow it to pursue development and potential commercialization of ERAS-0015 under a single global strategy.The drug candidate is being studied in a phase 1 dose escalation trial in patients with tumors driven by RAS mutations, Erasca said, adding that initial results are expected in H1.Financial terms were not disclosed.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618953846","isCrawlerRequest":true}